DK3119201T3 - Sildenafilopløsninger og fremgangsmåder til fremstilling og anvendelse heraf - Google Patents
Sildenafilopløsninger og fremgangsmåder til fremstilling og anvendelse heraf Download PDFInfo
- Publication number
- DK3119201T3 DK3119201T3 DK15764710.8T DK15764710T DK3119201T3 DK 3119201 T3 DK3119201 T3 DK 3119201T3 DK 15764710 T DK15764710 T DK 15764710T DK 3119201 T3 DK3119201 T3 DK 3119201T3
- Authority
- DK
- Denmark
- Prior art keywords
- sildenafil citrate
- water
- pharmaceutical composition
- solution
- ethanol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q5/00—Arrangements for simultaneous operation of antennas on two or more different wavebands, e.g. dual-band or multi-band arrangements
- H01Q5/50—Feeding or matching arrangements for broad-band or multi-band operation
- H01Q5/55—Feeding or matching arrangements for broad-band or multi-band operation for horn or waveguide antennas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q1/00—Details of, or arrangements associated with, antennas
- H01Q1/27—Adaptation for use in or on movable bodies
- H01Q1/28—Adaptation for use in or on aircraft, missiles, satellites, or balloons
- H01Q1/288—Satellite antennas
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q1/00—Details of, or arrangements associated with, antennas
- H01Q1/36—Structural form of radiating elements, e.g. cone, spiral, umbrella; Particular materials used therewith
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Astronomy & Astrophysics (AREA)
- Remote Sensing (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Aviation & Aerospace Engineering (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (18)
- SILDENAFILOPLØSNINGER OG FREMGANGSMÅDER TIL FREMSTILLING OG ANVENDELSE HERAF1. Farmaceutisk sammensætning, der omfatter: (a) en flydende bærer, der navnlig består af vand og mindst 20 % ethanol; og (b) sildenafilcitrat opløst i den flydende bærer ved en koncentration på mindst 7 mg/ml.
- 2. Farmaceutisk sammensætning ifølge krav 1, der omfatter et smagsstof og/eller et bitterhedsblokerende middel.
- 3. Farmaceutisk sammensætning, der omfatter (a) en flydende bærer, der navnlig består af vand, ethanol og mindre end 20 % acetone; og (b) sildenafilcitratet opløst i den flydende bærer ved en koncentration på mindst 10 mg/ml.
- 4. Farmaceutisk sammensætning ifølge krav 3, der omfatter mindst ét af et smagsstof eller bitterhedsblokerende middel.
- 5. Farmaceutisk sammensætning, der omfatter: (a) en flydende bærer, der omfatter vand, ethanol og 0,0075 % til 20 % acetone; og (b) sildenafilcitrat opløst i den flydende bærer ved en koncentration på mindst 10 mg/ml.
- 6. Farmaceutisk sammensætning, der omfatter: (a) en flydende bærer, der omfatter vand og mindst 60 % ethanol; og (b) sildenafilcitrat opløst i den flydende bærer ved en koncentration på mindst 7 mg/ml.
- 7. Sammensætning ifølge et hvilket som helst af de foregående krav 3 til 5, der omfatter et stabiliseringsmiddel.
- 8. Sammensætning ifølge krav 7, hvor stabiliseringsmidlet er udvalgt fra gruppen bestående af: diacetyleret monoglycerid, diethylglycolmonopalmitostearat, glycerylbehenat, glyceryldistearat, glycerylmonolinoleat, glycerylmono-oleat, glycerylmonostearat, selvemulgerende glycerylmonostearat, macrogolcetostearylethere, cetomacrogol 1000, 9 polyoxyl 20 cetostearylether, macrogol 15 hydroxystearat, macrogollaurilethere, laureth 4, lauromacrogol 400, macrogolmonomethylethere, macrogololeylethere, polyoxyl 10 oleylether, macrogolstearater, polyoxyl 40 stearater, menfegol, mono- og diglycerider, nonoxinoler, octoxinoler, poloxamere, polyoxyl castorolie, polyoxyl-hydrogenerede castorolier, polysorbater, propylenglycoldiacetat, propylenglycollaureater, propylenglycoldilaurat, propylenglycolmonolaureat, propylenglycolmonopalmitostearat, quillaia, sorbitanestere, saccharoseestere, tyloxapol, carrageenan, cellulose, ceratonia, dextrater, ethylcellulose, gastrisk mucin, hyprolose, hypromellose, hypermellosephthalat, methylcellulose, polyethylenoxid, polyvinylacetat, polyvinylalkoholer, silica, natriumstivelsesglycolat, tragacanth og xanthangummi.
- 9. Fremgangsmåde, der omfatter: (a) anbringelse af sildenafilcitrat i en kombination, der navnlig består af ethanol og vand, for at frembringe en blanding; og (b) opvarmning af blandingen for at frembringe en opløsning af sildenafilcitratet ved en koncentration på mindst 7 mg/ml.
- 10. Fremgangsmåde ifølge krav 9, der omfatter: afkøling af opløsningen og tilsætning af ethanol og/eller vand.
- 11. Fremgangsmåde, der omfatter: (a) tilvejebringelse af et første volumen acetone; og (b) tilsætning af et andet volumen, der navnlig består af ethanol og vand, for at frembringe et totalt opløsningsvolumen; og (c) opløsning af sildenafilcitrat ved en koncentration på mindst 7 mg/ml i forhold til det totale volumen.
- 12. Fremgangsmåde ifølge krav 11, der omfatter: opvarmning af opløsningen til en temperatur på ikke mindre end 5 °C under acetonens kogepunkt.
- 13. Fremgangsmåde ifølge krav 12, der omfatter fjernelse af mindst 25 % af acetonen.
- 14. Fremgangsmåde ifølge krav 12, der omfatter: afkøling af opløsningen og tilsætning af én eller flere alkoholer og/eller vand til en total alkoholkoncentration på mindst 34 %.
- 15. Oral doseringsform, der omfatter: en ydre belægning; og en flydende kerne, der omfatter et farmaceutisk sammensætning ifølge et af kravene 1 til 8.
- 16. Bukkal doseringsform, der omfatter: en bærer, der indeholder en farmaceutisk sammensætning ifølge et af kravene 1 til 8; og en indpakning, der er tilpasset til af forhindre fordampning af den flydende bærer under opbevaring.
- 17. Behandlingskit, der omfatter: en beholder, der indeholder en flerhed af enkeltdoser af en farmaceutisk sammensætning ifølge et af kravene 1 til 8; og en måleanordning, der er kalibreret til afmåling af en enkelt dosis fra beholderen.
- 18. Behandlingskit ifølge krav 17, hvor hver af de enkle doser er indeholdt i en separat beholder; og emballeringsmateriale tilpasset til at indeholde de separate beholdere.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955299P | 2014-03-19 | 2014-03-19 | |
| PCT/IB2015/052014 WO2015140748A2 (en) | 2014-03-19 | 2015-03-19 | Sildenafil solutions and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3119201T3 true DK3119201T3 (da) | 2018-05-28 |
Family
ID=54145440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15764710.8T DK3119201T3 (da) | 2014-03-19 | 2015-03-19 | Sildenafilopløsninger og fremgangsmåder til fremstilling og anvendelse heraf |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9968609B2 (da) |
| EP (2) | EP3372083A1 (da) |
| JP (1) | JP6744821B2 (da) |
| KR (1) | KR20160137584A (da) |
| CN (1) | CN106132204B (da) |
| AU (2) | AU2015233006B2 (da) |
| CA (1) | CA2942628C (da) |
| CL (1) | CL2016002318A1 (da) |
| CY (1) | CY1120187T1 (da) |
| DK (1) | DK3119201T3 (da) |
| EA (1) | EA032819B1 (da) |
| ES (1) | ES2668915T3 (da) |
| HR (1) | HRP20180773T1 (da) |
| HU (1) | HUE038431T2 (da) |
| IL (1) | IL247840B (da) |
| LT (1) | LT3119201T (da) |
| MX (1) | MX371276B (da) |
| NO (1) | NO2723977T3 (da) |
| PL (1) | PL3119201T3 (da) |
| PT (1) | PT3119201T (da) |
| RS (1) | RS57206B1 (da) |
| SG (2) | SG11201607507VA (da) |
| SI (1) | SI3119201T1 (da) |
| WO (1) | WO2015140748A2 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2723977T3 (da) | 2014-03-19 | 2018-03-10 | ||
| JP6902372B2 (ja) * | 2017-02-28 | 2021-07-14 | ヱスビー食品株式会社 | 苦味抑制用組成物 |
| CA3086881A1 (en) * | 2017-12-26 | 2019-07-04 | Ftf Pharma Private Limited | Liquid oral formulations for pde v inhibitors |
| WO2020212931A1 (en) * | 2019-04-18 | 2020-10-22 | Vigorous Solutions Ltd. | Liquid sildenafil citrate compositions |
| US20220387433A1 (en) * | 2019-11-12 | 2022-12-08 | American Regent, Inc. | Type v phosphodiesterase inhibitor compositions, methods of making them and methods of using them in preventing or treating elevated pulmonary vascular pressure or pulmonary hemorrhages |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785984A (en) * | 1993-02-05 | 1998-07-28 | Kao Corporation | Taste-modifying method and bitterness-decreasing method |
| WO1994017675A1 (en) * | 1993-02-05 | 1994-08-18 | Kao Corporation | Taste modifying method and bitter taste reducing method |
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
| US6531114B1 (en) | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| TWI224966B (en) | 1999-11-02 | 2004-12-11 | Pfizer | Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient |
| AU3048501A (en) * | 1999-11-18 | 2001-05-30 | Natco Pharma Limited | An improved pharmaceutical composition for treating male erectile dysfunction |
| KR100848344B1 (ko) | 2000-02-04 | 2008-07-25 | 유서홍 | 담즙산 함유 청정 수용액 제형의 제조 |
| AU2001273545A1 (en) | 2000-07-19 | 2002-01-30 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
| US20030216407A1 (en) | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| US7611728B2 (en) | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
| EP1781239A2 (en) | 2003-11-17 | 2007-05-09 | Patus Ltd | Compositions effective in altering the perception of malodor |
| JP2007517803A (ja) | 2004-01-05 | 2007-07-05 | テバ ファーマシューティカル インダストリーズ リミティド | シルデナフィル塩基とクエン酸塩の製造方法 |
| CN1925860A (zh) * | 2004-01-05 | 2007-03-07 | 特瓦制药工业有限公司 | 制备西地那非碱及其柠檬酸盐的方法 |
| US7727565B2 (en) | 2004-08-25 | 2010-06-01 | Cadbury Adams Usa Llc | Liquid-filled chewing gum composition |
| US7879828B2 (en) | 2005-03-14 | 2011-02-01 | Wyeth Llc | Tigecycline compositions and methods of preparation |
| US7556487B2 (en) | 2006-03-29 | 2009-07-07 | Intergum Gida Sinayi ve Ticaret A.S. | Apparatus for making center-filled chewing gum pieces |
| FR2906140B1 (fr) * | 2006-09-22 | 2008-12-05 | Philippe Perovitch | Forme galenique pour l'administration par voie trans-muqueuse de principes actifs |
| DE502008002360D1 (de) | 2007-06-19 | 2011-03-03 | Symrise Ag | Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck |
| EP2072044A1 (en) * | 2007-12-19 | 2009-06-24 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising a liquid or flowable core composition |
| WO2009125415A1 (en) | 2008-04-07 | 2009-10-15 | Hetero Research Foundation | Amorphous form of sildenafil citrate |
| FR2939321B1 (fr) | 2008-12-05 | 2011-08-26 | Philippe Perovitch | Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique. |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| DE102010049708A1 (de) * | 2010-10-28 | 2012-05-03 | Hexal Ag | Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe |
| RU2611403C1 (ru) * | 2011-12-05 | 2017-02-21 | Суда Лимитед | Составы в форме спрея для перорального введения и способы введения силденафила |
| GB2497933B (en) | 2011-12-21 | 2014-12-24 | Londonpharma Ltd | Drug delivery technology |
| IN2014KN02583A (da) * | 2012-05-16 | 2015-05-08 | Techfields Pharma Co Ltd | |
| US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| NO2723977T3 (da) * | 2014-03-19 | 2018-03-10 |
-
2012
- 2012-04-16 NO NO12802846A patent/NO2723977T3/no unknown
-
2015
- 2015-03-19 EP EP18161634.3A patent/EP3372083A1/en not_active Withdrawn
- 2015-03-19 RS RS20180533A patent/RS57206B1/sr unknown
- 2015-03-19 SG SG11201607507VA patent/SG11201607507VA/en unknown
- 2015-03-19 LT LTEP15764710.8T patent/LT3119201T/lt unknown
- 2015-03-19 PT PT157647108T patent/PT3119201T/pt unknown
- 2015-03-19 EA EA201691871A patent/EA032819B1/ru unknown
- 2015-03-19 EP EP15764710.8A patent/EP3119201B1/en active Active
- 2015-03-19 CA CA2942628A patent/CA2942628C/en active Active
- 2015-03-19 HU HUE15764710A patent/HUE038431T2/hu unknown
- 2015-03-19 MX MX2016012154A patent/MX371276B/es active IP Right Grant
- 2015-03-19 AU AU2015233006A patent/AU2015233006B2/en not_active Ceased
- 2015-03-19 KR KR1020167029017A patent/KR20160137584A/ko not_active Application Discontinuation
- 2015-03-19 PL PL15764710T patent/PL3119201T3/pl unknown
- 2015-03-19 SI SI201530249T patent/SI3119201T1/en unknown
- 2015-03-19 WO PCT/IB2015/052014 patent/WO2015140748A2/en active Application Filing
- 2015-03-19 ES ES15764710.8T patent/ES2668915T3/es active Active
- 2015-03-19 CN CN201580013951.5A patent/CN106132204B/zh not_active Expired - Fee Related
- 2015-03-19 SG SG10201808038TA patent/SG10201808038TA/en unknown
- 2015-03-19 DK DK15764710.8T patent/DK3119201T3/da active
- 2015-03-19 JP JP2016558141A patent/JP6744821B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-14 CL CL2016002318A patent/CL2016002318A1/es unknown
- 2016-09-15 US US15/265,897 patent/US9968609B2/en not_active Expired - Fee Related
- 2016-09-15 IL IL247840A patent/IL247840B/en active IP Right Grant
-
2018
- 2018-04-12 US US15/951,197 patent/US10211534B2/en active Active
- 2018-05-03 CY CY20181100459T patent/CY1120187T1/el unknown
- 2018-05-17 HR HRP20180773TT patent/HRP20180773T1/hr unknown
- 2018-10-16 AU AU2018250378A patent/AU2018250378B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018250378B2 (en) | Sildenafil solutions and methods of making and using same | |
| UA76144C2 (uk) | Фармацевтичний розчин арипіпразолу для внутрішнього вживання | |
| TW201023859A (en) | Pharmaceutical composition of a potent HCV inhibitor for oral administration | |
| NO334441B1 (no) | Preparat for behandling av vanlig forkjølelse. | |
| US9180124B2 (en) | Nicotine containing formulation | |
| DK2908834T3 (da) | Hidtil ukendte formuleringer med planteekstrakter | |
| JP2024050598A (ja) | 医薬製剤 | |
| TW201431567A (zh) | 阿托莫西汀（ａｔｏｍｏｘｅｔｉｎｅ）溶液 | |
| JP6549428B2 (ja) | 経口組成物 | |
| US10426781B2 (en) | Oral formulation and suspension of an oncology drug | |
| JP2012025676A (ja) | スマトリプタンコハク酸塩を含有する内用液剤 | |
| EP2908859A1 (en) | Aripiprazole formulations | |
| CN114159387B (zh) | 一种氢溴酸右美沙芬口服溶液 | |
| JP2017523231A5 (da) | ||
| CN102940610A (zh) | 维生素b6组合物冻干口腔崩解片及其制备方法 | |
| RU2607965C1 (ru) | Жидкая лекарственная форма фенспирида и способ ее получения | |
| JP2017523231A (ja) | 癌治療用アファチニブ医薬キット | |
| JP5433508B2 (ja) | ゾルピデム酒石酸塩含有内用液剤 | |
| TW201628635A (zh) | 用以改善糖尿病視網膜病變之中草藥組合物及其用途 | |
| KR20240006523A (ko) | 티자니딘 액상 제제 및 이의 용도 | |
| RU2410088C2 (ru) | Фармацевтическая композиция в форме сиропа и способ ее получения | |
| JP2003192574A (ja) | 弱アルカリで安定化される薬剤を含む医薬用液剤 |